Force Health Care

U. S. Food and Drug Administration (FDA) revoked the license for Avastin treat breast cancer. Avastin is an anti-cancer drug which was developed by the Roche Company. According to health Advisory Committees survey data for many years. The FDA says that it is considering withdrawal because Avastin doesn’t show enough promise against breast cancer. Most scientific experts consider this benefit progression-free survival, ” sufficient for full approval, and many oncologists have been using Avastin as an off-label” drug for this purpose And, unlike the case with the Avastin study completed by a prestigious NIH-funded consortium, the FDA should confidently rely on their results.

Avastin is a novel medicine that inhibits the growth of a network of blood vessels that supply nutrients and oxygen to cancerous tissues . Avastin (Bevacizumab, Avastin) is a recombinant humanized monoclonal antibody. Avastin currently is approved by the U. S. Food and Drug Administration (FDA) for treating lung and colon cancer, but many doctors use it to treat breast cancer. Avastin have serious side effects, Avastin also has serious, if infrequent, side effects, some of which can be lethal. The most serious side effects associated with Avastin, in some cases resulting in death, are gastrointestinal perforation, wound healing complications, hemorrhage, and blood clots. The FDA is also concerned that Avastin has bad side effects. Avastin was approved in 2008, listed on chemotherapy combination treatment Delay the growth of breast cancer five months. FDA studies have found Avastin only prolonged survival of patients with breast cancer to three months. but There is any evidence to prove to prolong survival of patients with advanced breast cancer.